AgomAb Therapeutics NV (NASDAQ:AGMB) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of AgomAb Therapeutics NV (NASDAQ:AGMB) have earned a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $37.50.

AGMB has been the subject of several research analyst reports. Wall Street Zen lowered shares of AgomAb Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. B. Riley Financial started coverage on AgomAb Therapeutics in a research report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 target price on the stock. HC Wainwright began coverage on AgomAb Therapeutics in a research note on Monday, June 22nd. They issued a “buy” rating and a $35.00 target price for the company. Cantor Fitzgerald assumed coverage on AgomAb Therapeutics in a report on Wednesday, August 19th. They issued an “overweight” rating on the stock. Finally, Piper Sandler initiated coverage on shares of AgomAb Therapeutics in a report on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price target on the stock.

AgomAb Therapeutics Stock Performance

Shares of NASDAQ:AGMB opened at $13.06 on Friday. The business has a 50 day simple moving average of $13.44 and a two-hundred day simple moving average of $12.50. AgomAb Therapeutics has a 1 year low of $8.75 and a 1 year high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last issued its earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. As a group, equities research analysts predict that AgomAb Therapeutics will post -1.76 EPS for the current fiscal year.

About AgomAb Therapeutics

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.